Cancer therapy-related cardiac dysfunction (CTRCD) is a well-known complication in breast cancer patients exposed to anthracyclines and Human Epidermal Growth Factor Receptor 2 (HER2) targeted therapy. However, the incidence of CTRCD in unselected contemporary breast cancer populations treated according to curren...
V. Vinje, E. Orstad, G. Gulati et al.· European Heart Journal· 0 citations
BACKGROUND
Left atrial (LA) reservoir (LASr), conduit (LAScd) and contractile (LASct) strain are known to reflect atrial remodeling and is prognostic in atrial fibrillation (AF) and heart failure. Evidence is scarce on prediction of major adverse cardiovascular events (MACE) in general populations. LA mechanical disper...
M. Solberg, P. Rønningen, T. Berge et al.· International Journal of Car...· 0 citations
Echocardiographic trait characterization showed that the AI–ECG HF prediction score aligned primarily with measures of systolic function, particularly GLS, while also being associated with diastolic-related abnormalities in patients with preserved LVEF.
E. Stenhede, E. Orstad, T. Omland et al.· European Heart Journal - Dig...· 0 citations
The CARE study is a large prospective observational cardio-oncology study evaluating the incidence of CTRCD after contemporary breast cancer therapy regimens and the performance of the HFA-ICOS risk stratification tool and follow-up strategies in routine cardio-oncology care.
V. Vinje, E. Orstad, G. Gulati et al.· European Heart Journal, Supp...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.